Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Amortization of Deferred Charges of $2.2 million for Q2 2026, up 63.88% year-over-year from $1.3 million in Q2 2025, and down 2.75% on a QoQ basis from $2.3 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Amortization of Deferred Charges for 16 years, with the latest figure at $2.2 million in Q2 2026.
- Amortization of Deferred Charges for Q2 2026 came in at $2.2 million, up 63.88% year-over-year; the trailing twelve-month figure through Jun 2026 was $7.1 million (down 12.27% YoY), and the FY2025 annual result was $8.0 million, up 46.37% from the prior year.
- Amortization of Deferred Charges fell to $2.2 million in Q2 2026, from $2.3 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $6.0 million in Q4 2023 and troughed at $500000.0 in Q2 2022.
- A 5-year average of $1.9 million and a median of $1.3 million in 2025 frame the typical range for Amortization of Deferred Charges.
- The widest annual swing landed in 2022, when Amortization of Deferred Charges plunged 88.37%; it then surged 1026.6% in 2023.
- A 5-year view of Amortization of Deferred Charges shows it stood at $530000.0 in 2022, then surged by 1026.6% to $6.0 million in 2023, then dropped by 8.69% to $5.5 million in 2024, then plunged by 75.42% to $1.3 million in 2025, then soared by 63.88% to $2.2 million in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $2.2 million in Q2 2026, $2.3 million in Q1 2026, and $1.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.20 Mn |
| Jun 30, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.26 Mn |
| Mar 31, 2026 | 2.26 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2023 | 532,000.00 |
| Mar 31, 2023 | 532,000.00 |
| Dec 31, 2022 | 530,000.00 |
| Dec 31, 2022 | 530,000.00 |
| Sep 30, 2022 | 529,000.00 |
| Sep 30, 2022 | 529,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 526,000.00 |
| Mar 31, 2022 | 526,000.00 |
| Dec 31, 2021 | 4.50 Mn |
| Dec 31, 2021 | 4.50 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Sep 30, 2021 | 4.40 Mn |